ClinicalTrials.gg
CompletedNCT04989816DG-06Updated Nov 21, 2024Results posted

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

A Phase 2 interventional study of Trastuzumab Deruxtecan in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, sponsored by AstraZeneca. Completed at 24 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Adenocarcinoma with a site in China — 33 open to participants now, 42 under way, 12 of them phase 3. Adenocarcinoma · China.

Enrollment
35th of 68
95 · median 98
Started
2021
with 5 others
Phase 2
26 of 77
9 open now
Registered
39th of 77
by date
Lead sponsor
3 of 77
AstraZeneca

Among the 77 studies in Adenocarcinoma with a site in China, this one is the 35th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2021, is one of 26 in phase 2, and was the 39th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

33 of the 77 studies in Adenocarcinoma with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Adenocarcinoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent

03

Conditions studied

  • Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Keywords

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • HER2
  • Trastuzumab
  • Deruxtecan
  • T-DXd
  • DS-8201a
  • ERBB2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. documented gastric or GEJ adenocarcinoma
  3. Disease progression on or after ≥ 2 prior platinum and fluoropyrimidine agents for advanced/ disease
  4. PS 0-1
  5. Willing and able to provide an adequate newly-acquired tumour sample for confirmation of status
  6. ≥ 50%

Exclusion criteria

Exclusion Criteria:

  1. Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and CART. Drainage and CART.
  2. Spinal cord compression or unless asymptomatic, stable, and not requiring
  3. Active primary immunodeficiency, known , active , infection.
  4. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  5. History of non-infectious pneumonitis/ILD, current ILD, or where suspected ILD that cannot be ruled out by imaging at screening.
  6. Lung-specific intercurrent severe illnesses.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    T-DXd arm

    T-DXd monotherapy

    Drug: Trastuzumab Deruxtecan

Interventions

  • Trastuzumab deruxtecan (T-DXd) by intravenous infusion

    Also known as: DS8201a; AZD4552; T-DXd

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)

    Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months

  2. Best Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)

    The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months

Secondary outcomes

  1. Progression-free Survival (PFS) Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months

  2. Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 3 months using the Kaplan-Meier technique

  3. Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 6 months using the Kaplan-Meier technique

  4. Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 9 months using the Kaplan-Meier technique

  5. Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 12 months using the Kaplan-Meier technique

  6. Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 15 months using the Kaplan-Meier technique

  7. Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 18 months using the Kaplan-Meier technique

  8. Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)

    PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 21 months using the Kaplan-Meier technique

  9. Disease Control Rate (DCR) Based on Independent Central Review (ICR)

    Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD)

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months

  10. Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12

    Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD) for at least 11 weeks (ie 12 weeks - 1 week to allow for an early assessment within the assessment window)

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. DCR assessed at Week 12

  11. Duration of Response (DoR) Based on Independent Central Review (ICR)

    DoR defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) or death in the absence of progression based on investigator assessments by using RECIST version 1.1

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months

  12. Overall Survival (OS) Based on Independent Central Review (ICR)

    OS based on ICR is defined as the time from date of enrolment until the date of death due to any cause

    Time frame: From date of enrolment until death due to any cause. Assessed up to approximately 30 months (from date of first subject in to data cut-off 28February2024)

  13. Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)

    Best percentage change based on ICR is defined as the best change in target lesion tumour size from baseline (maximum reduction or minimum increase from baseline in the absence of a reduction)

    Time frame: Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months

07

Results

Posted Nov 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneT-DXd Arm
Started95
Received treatment95
Completed15
Not completed80
Withdrew: Death77
Withdrew: Lost to follow-up3

Outcome measures

PrimaryConfirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)

Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months
Reported as:
Number · Percentage of Participants
Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)
Percentage of ParticipantsT-DXd Arm
Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)28.8 (18.8 to 40.6)
PrimaryBest Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)

The best response based on the overall visit responses from each RECIST 1.1 assessment or the last evaluable assessment in the absence of RECIST 1.1 progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 19.3 months
Reported as:
Count of participants · Participants
Best Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR)
ParticipantsT-DXd Arm
Complete response (confirmed after at least 4 weeks)1
Partial response (confirmed after at least 4 weeks)20
Stable disease37
Progression14
Not evaluable1
SecondaryProgression-free Survival (PFS) Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Reported as:
Median · Months
Progression-free Survival (PFS) Based on Independent Central Review (ICR)
MonthsT-DXd Arm
Progression-free Survival (PFS) Based on Independent Central Review (ICR)5.7 (4.0 to 6.8)
SecondaryProgression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 3 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 3 Months Based on Independent Central Review (ICR)69.0 (56.8 to 78.4)
SecondaryProgression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 6 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 6 Months Based on Independent Central Review (ICR)43.4 (30.8 to 55.3)
SecondaryProgression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 9 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 9 Months Based on Independent Central Review (ICR)27.1 (16.2 to 39.3)
SecondaryProgression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 12 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 12 Months Based on Independent Central Review (ICR)16.7 (8.0 to 28.1)
SecondaryProgression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 15 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 15 Months Based on Independent Central Review (ICR)11.9 (4.7 to 22.8)
SecondaryProgression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 18 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 18 Months Based on Independent Central Review (ICR)4.0 (0.4 to 15.6)
SecondaryProgression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)

PFS based on ICR is defined as the time from date of enrolment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from therapy or receives another anti-cancer therapy prior to progression

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Calculated at 21 months using the Kaplan-Meier technique
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Progression-free Survival (PFS) Rate at 21 Months Based on Independent Central Review (ICR)4.0 (0.4 to 15.6)
SecondaryDisease Control Rate (DCR) Based on Independent Central Review (ICR)

Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD)

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Based on Independent Central Review (ICR)
Percentage of participantsT-DXd Arm
Disease Control Rate (DCR) Based on Independent Central Review (ICR)79.5 (68.4 to 88.0)
SecondaryDisease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12

Disease control rate based on ICR according to RECIST version 1.1 was defined as the rate of best objective response of complete response (CR), partial response (PR) or stable disease (SD) for at least 11 weeks (ie 12 weeks - 1 week to allow for an early assessment within the assessment window)

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. DCR assessed at Week 12
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 12
Percentage of participantsT-DXd Arm
Disease Control Rate (DCR) Based on Independent Central Review (ICR) at Week 1274.0 (62.4 to 83.5)
SecondaryDuration of Response (DoR) Based on Independent Central Review (ICR)

DoR defined as the time from the date of first documented OR (confirmed CR or confirmed PR) until date of documented progression (PD) or death in the absence of progression based on investigator assessments by using RECIST version 1.1

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Reported as:
Median · Months
Duration of Response (DoR) Based on Independent Central Review (ICR)
MonthsT-DXd Arm
Duration of Response (DoR) Based on Independent Central Review (ICR)6.7 (4.6 to 8.8)
SecondaryOverall Survival (OS) Based on Independent Central Review (ICR)

OS based on ICR is defined as the time from date of enrolment until the date of death due to any cause

Time frame:
From date of enrolment until death due to any cause. Assessed up to approximately 30 months (from date of first subject in to data cut-off 28February2024)
Reported as:
Median · Months
Overall Survival (OS) Based on Independent Central Review (ICR)
MonthsT-DXd Arm
Overall Survival (OS) Based on Independent Central Review (ICR)11.1 (7.7 to 13.7)
SecondaryBest Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)

Best percentage change based on ICR is defined as the best change in target lesion tumour size from baseline (maximum reduction or minimum increase from baseline in the absence of a reduction)

Time frame:
Tumour assessments every 6 weeks from 1st dose of treatment until Recist 1.1 defined radiological progressive disease. Assessed up to a maximum of 22 months
Reported as:
Mean · Percentage Change
Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)
Percentage ChangeT-DXd Arm
Best Percentage Change in Sum of Diameters of Measurable Tumours Based on Independent Central Review (ICR)-22.55 ± 29.682

Adverse events

Collected over From the signature of the informed consent form until 40 (+7) days after the last dose of study treatment or until the start of the first subsequent anticancer therapy after discontinuation of study treatment, whichever comes first (maximum treatment duration of 19.3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DXd77/95 (81.1%)40/95 (42.1%)93/95 (97.9%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventT-DXd
Platelet count decreasedInvestigations6/95
AnaemiaBlood and lymphatic system disorders5/95
Covid-19Infections and infestations5/95
PneumoniaInfections and infestations5/95
AstheniaGeneral disorders4/95
Covid-19 pneumoniaInfections and infestations4/95
Gastrointestinal haemorrhageGastrointestinal disorders3/95
Hepatic function abnormalHepatobiliary disorders2/95
Febrile neutropeniaBlood and lymphatic system disorders2/95
ThrombocytopeniaBlood and lymphatic system disorders2/95
Most frequent other events
Showing 10 of 49
Most frequent other events
EventT-DXd
AnaemiaBlood and lymphatic system disorders73/95
White blood cell count decreasedInvestigations69/95
Neutrophil count decreasedInvestigations58/95
Platelet count decreasedInvestigations50/95
NauseaGastrointestinal disorders41/95
Decreased appetiteMetabolism and nutrition disorders38/95
HypoalbuminaemiaMetabolism and nutrition disorders37/95
Aspartate aminotransferase increasedInvestigations30/95
VomitingGastrointestinal disorders30/95
Weight decreasedInvestigations27/95

Baseline characteristics

Age, Continuous
Age, Continuous(Years)T-DXd Arm
Median60 (28 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)T-DXd Arm
Female22
Male73
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)T-DXd Arm
Hispanic or Latino0
Not Hispanic or Latino95
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T-DXd Arm
American Indian or Alaska Native0
Asian95
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

24 sites
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510062, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Jinan, 250001, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Nan Chong, 637000, China
  • Research Site
    Nanchang, 330029, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Wuhan, 430000, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zhengzhou City, 450000, China
  • Research Site
    Zhengzhou, 450008, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . A Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jun 2023, 21 months.

Results were first posted in Nov 2024, 1 year 5 months after primary completion.

Of 93 phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 82. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Aug 4, 2021
StartActual
Aug 20, 2021
Primary completionActual
Jun 16, 2023
CompletionActual
Feb 28, 2024
Results first posted
Nov 21, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04989816
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 4, 2021
Start date
Aug 20, 2021
Primary completion
Jun 16, 2023
Completion
Feb 28, 2024
Results posted
Nov 21, 2024
Last update
Nov 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion